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Phosphorylation of endogenous inhibitor pro-
teins for type-1 Ser/Thr phosphatase (PP1) pro-
vides a mechanism for reciprocal coordination
of kinase and phosphatase activities. A myosin
phosphatase inhibitor protein CPI-17 is phos-
phorylated at Thr38 through G-protein-medi-
ated signals, resulting in a >1000-fold increase
in inhibitory potency.We show here the solution
NMR structure of phospho-T38-CPI-17 with
rmsd of 0.36 ± 0.06 A˚ for the backbone second-
ary structure, which reveals how phosphoryla-
tion triggers a conformational change and
exposes an inhibitory surface. This active con-
formation is stabilized by the formation of a
hydrophobic core of intercalated side chains,
which is not formed in a phospho-mimetic D38
form of CPI-17. Thus, the profound increase in
potency of CPI-17 arises from phosphorylation,
conformational change, and hydrophobic sta-
bilization of a rigid structure that poses the
phosphorylated residue on the protein surface
and restricts its hydrolysis by myosin phospha-
tase. Our results provide structural insights into
transduction of kinase signals by PP1 inhibitor
proteins.
INTRODUCTION
Type-1 Ser/Thr phosphatase (PP1) is conserved among all
eukaryotes and is responsible for regulation of a plethora
of cellular functions. A specific multisubunit form of PP1,
called myosin phosphatase, is a ubiquitous enzyme that
functions in various signaling circuits (Hartshorne et al.,
2004). Myosin phosphatase consists of a catalytic subunitStructure 15, 1591–160of PP1 and a myosin targeting MYPT1 subunit with an
accessory M21 subunit (Hartshorne et al., 2004). The N-
terminal ankyrin-repeat domain of MYPT1, including a
PP1 binding site, functions as an allosteric regulator of the
catalytic subunit (Terrak et al., 2004). On the other hand,
the C-terminal domain is phosphorylated by multiple ki-
nases, ROCK, ZIPK, and ILK, resulting in the inhibition of
myosin phosphatase (Trinkle-Mulcahy et al., 1995; Kimura
et al., 1996; MacDonald et al., 2001; Muranyi et al., 2002).
In smooth muscle, agonist-induced activation of G protein
enhances the activity of Ca2+/calmodulin-dependentmyo-
sin light-chain kinase and coincidently suppresses the ac-
tivity of myosin phosphatase via the activation of kinases
ROCK and PKC (Kitazawa et al., 1991; Somlyo and Som-
lyo, 2003). The inhibition of myosin phosphatase is re-
quired for robust and sustained contraction of smooth
muscle in response to agonist stimuli (Dimopoulos et al.,
2007), as well as regulation of cytoskeletal reorganization
during cell migration (Kawano et al., 1999) and cytokinesis
(Matsumura, 2005).
In addition to direct phosphorylation of the MYPT1 sub-
unit,myosinphosphatase is regulatedbyaspecific inhibitor
protein, CPI-17, that is predominantly expressed in smooth
muscles and neurons (Eto et al., 1997, 2002a; Woodsome
et al., 2001). Phosphorylation of CPI-17 at Thr38 is neces-
sary and sufficient to convert the protein into a potent in-
hibitor of myosin phosphatase (Eto et al., 1995; Kitazawa
et al., 2000; Koyama et al., 2000; Pang et al., 2005). By con-
trast, othermultisubunit formsof PP1 in cells are insensitive
to phospho-CPI-17 (P-CPI-17) (Senba et al., 1999). One
example is a glycogen-bound form of PP1 holoenzyme,
which binds P-T38-CPI-17 but dephosphorylates it (Eto et
al., 2004). With myosin phosphatase, there is binding of
P-T38-CPI-17, but the hydrolysis step is arrested, resulting
in formation of inactive complex. Thus, P-T38-CPI-17 can
be a substrate or an inhibitor of different forms of PP1,
depending on regulatory subunits (Eto et al., 2004).
In smooth-muscle cells, rapid phosphorylation of CPI-
17 at Thr38 occurs in parallel to phosphorylation of myosin2, December 2007 ª2007 Elsevier Ltd All rights reserved 1591
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NMR Structure of Phospho-CPI-17Figure 1. Inhibitory Domain of CPI-17 Family
(A) Amino acid sequence of CPI-17 family of PP1 inhibitor proteins. Asterisk indicates Thr38, and arrows indicate Trp55, Ile77, Leu80, and Leu81.
Cylinders show regions in helices A to D.
(B) 1H-15N HSQC spectrum. 15N single labeled P- (red), U- (gray), and D38-CPI-17 (22–120) (blue) were subjected to HSQC measurement at 1 mM
protein concentration. All amide resonances were assigned to each residue (data not shown). Box line indicates the area shown in Figure S2. Asterisk
indicates fold-back peak of resonance derived from side-chain amide.1592 Structure 15, 1591–1602, December 2007 ª2007 Elsevier Ltd All rights reserved
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NMR Structure of Phospho-CPI-17via activation of Ca2+-dependent PKC, followed by pro-
longed phosphorylation, maintained via RhoA/ROCK sig-
nal (Dimopoulos et al., 2007). Phosphorylation of CPI-17
is reduced through a cGMP-dependent pathway in res-
ponse to nitric oxide release, in parallel to muscle relaxa-
tion (Bonnevier and Arner, 2004; Etter et al., 2001). Thus,
in smooth muscles CPI-17 functions to mediate multiple
signals into myosin phosphatase and thereby control
myosin phosphorylation and contraction. Fluctuation in
the expression and the phosphorylation levels of CPI-17
is associated with smooth-muscle-related diseases,
such as intestinal bowel disease (Ohama et al., 2003),
asthma (Sakai et al., 2005), pulmonary hypertension (Dak-
shinamurti et al., 2005), and diabetic dysfunction of
smoothmuscle (Chang et al., 2006; Xie et al., 2006). In Pur-
kinje neurons, CPI-17 is essential to maintain G-protein-
mediated AMPA receptor internalization and generate
long-term synaptic depression in response to stimulation
(Eto et al., 2002a). In addition, the upregulation of CPI-17
was found in tumor cells, which causes hyperphosphory-
lation of tumor suppressormerlin (NF2) and transformation
of cells (Jin et al., 2006). Therefore, CPI-17 poses a po-
tential target of pharmaceutical approaches for these
diseases.
Determination of the three-dimensional (3D) structure of
unphospho-CPI-17 by NMR revealed a 2 3 2 pairing of
a four-helix bundle, forming a unique V-shape structure
(Ohki et al., 2001). The phosphorylation site, Thr38, is lo-
cated in a loop structure (P loop) at the N terminus, sitting
in a cavity between helices (Ohki et al., 2001). When Thr38
is substituted for Asp tomimic phosphorylation, the P loop
becomesexposed to solvent, suggesting aconformational
change of the P loop upon activation of CPI-17 (Ohki et al.,
2003). However, structural analysis of the basis for en-
hanced inhibition of myosin phosphatase by CPI-17 was
limited because the D38-form of CPI-17 is significantly
less potent, compared with phospho (P)-T38-CPI-17
(Ohki et al., 2003). We concluded that despite a conforma-
tional change in the D38 protein, this structure was not the
same as that of the highly potent and fully activated P-
T38-CPI-17. Therefore, we prepared CPI-17 protein fully
phosphorylated with PKC and determined the 3D struc-
ture by using multidimensional NMR techniques. The 3D
structure indicates a global conformational switch upon
phosphorylation of CPI-17 at Thr38, shows differences
relative to the phospho-mimetic D38 structure, and
exposes novel interactions between P-CPI-17 andmyosin
phosphatase.
RESULTS
Phosphorylation of CPI-17
The inhibitory domain of CPI-17 comprised of residues
22–120 is conserved among the CPI-17 family of PP1Structure 15, 1591–1602inhibitor proteins, such as PHI-1, KEPI, and GBPI (Fig-
ure 1A). The recombinant 13C/15N-labeled 22–120 protein
was phosphorylated to completion by extended incuba-
tion with purified PKC (Figure S1, see the Supplemental
Data available with this article online) and subjected to
a series of multidimensional NMR experiments (Figure 1B
and Figures S2 and S3). Figure 1B shows the 1H-15N
HSQC spectrum of 13C/15N-labeled P-CPI-17 (red) super-
imposed on the previous spectra of unphosphorylated
(gray) and Asp-substituted D38-CPI-17 (blue) (22–120)
proteins (Ohki et al., 2003). Overall, the profiles of HSQC
spectra in the full-scale chart are similar in all three forms
of CPI-17 examined by NMR (Figure 1B). The backbone
amide resonance of Thr38 is shifted to downfield upon
phosphorylation (Figure 1B and Figure S2). This phos-
phorylation-dependent downfield shift is consistent with
a previous report on phosphorylation of the tau protein
(Landrieu et al., 2006). Concomitantly, a large chemical
shift change of amide resonances from the neighbor resi-
dues was observed in the phosphorylation loop (P loop),
such as V39 and Y41 (Figure 1C). In addition, clusters of
moderate changes in chemical shift were observed from
residues around A helix (residue 44–46) and B helix (resi-
due 74–83) (Figure 1C, inset). The chemical shifts of these
residues in P-T38-CPI-17 did not match those in the D38
form of CPI-17 (Figure 1B and Figure S2, blue). This sug-
gests that the conformation of the phosphorylated protein
differs from the conformation of the protein with a ‘‘phos-
phomimetic’’ mutation to introduce an Asp at the same
residue. There was no evidence of multiple conformation
states in the spectrum of P-T38-CPI-17.
Structure of Phospho-T38-CPI-17
The 3D structure of P-T38-CPI-17 was calculated with
1,518 structural restraints obtained from the NMR data
(Figure S3), summarized in Table S1. Overall, the topology
of P-T38-CPI-17 is composed of a long loop with the
phosphorylation site, Thr38, followed by a left-handed
four-helix bundle (termed A to D from the N terminus) (Fig-
ure 2). The four helices are arranged in an antiparallel
orientation. The structure of residues 22 to 31 at the N
terminus of the truncated protein was in a flexible confor-
mation, seen by lack of long-range NOE. This conclusion
is supported by very small heteronuclear 15N-{1H} NOE
values (Figure S4) and the fast H-D exchange rates (data
not shown) of these ten residues. In contrast, the con-
served region of residues 32 to 40 with phospho-Thr38
(P-Thr38), termed the P loop, converged into a single
conformation with a backbone rmsd of 1.18 ± 0.27 A˚,
with relatively higher heteronuclear 15N-{1H} NOE values
(Figure S4, red). The P-Thr38 side chain is exposed to
solvent, and the P loop lays on the surface of the four-helix
bundle. The side chains of Val37 and Val39 face into the
protein, making contacts with Ile56 and Tyr41/Val52/
Ile77, respectively. These two Val residues function to(C) Chemical shift change of amide resonance induced by phosphorylation at Thr38. The chemical shift change was calculated as described in
Experimental Procedures and plotted against residue numbers. Regions of the phosphorylation site and a helices are indicated above as a circle
and boxes, respectively., December 2007 ª2007 Elsevier Ltd All rights reserved 1593
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NMR Structure of Phospho-CPI-17Figure 2. Solution NMR Structure of
Phospho-CPI-17(22–120)
(A) Stereo view of the backbone of 20 superim-
posed structures obtained by NMR analysis.
Red indicates the region of a helix.
(B) Ribbon representation of an energy-mini-
mized average structure. In the ribbon model,
the flexible N-terminal 31 residues are not
depicted. T38 and residues involved in hydro-
phobic clustering are drawnwith ball-and-stick
side chains labeled with residue numbers to
facilitate identification, and the helices are
labeled with upper case letters.
(C) Space-filling representation with molecular
surface potential, superimposed on backbone
structure (green). Red and blue on surface indi-
cate regions of negative and positive charges,
respectively. A side chain of P-T38 is drawn as
ball and stick.anchor the P loop to the four-helix bundle by hydrophobic
interactions of the aliphatic side chains.
Comparison between Unphospho-, Phospho-,
and Asp-Substituted CPI-17 Structures
Comparison of P-T38-CPI-17 structure with that of the
unphospho-form (U-CPI-17) and D38-form (Ohki et al.,
2003) reveals global conformational change in response
to phosphorylation (Figure 3) (Table S2). Themost remark-
able difference is the position of the key residue, Thr38,
whose side chain comes out of a cavity between A and
B helices upon phosphorylation. When structures are
superimposed with the A/D helix pair for alignment (Fig-
ure 3, bottom), the phosphorylation at Thr38 is seen to trig-
ger a swinging motion of the P loop around the A helix, re-
sulting in 8.1 A˚movement of residue 38. The swing of the P
loop is coupled with a right-handed rotation of A helix by
29 degrees, along with a complementary rotation of the
D helix. These rotations expose new surfaces of both
helices that become available for binding to myosin phos-
phatase. Similar to U-CPI-17, the A/D helix pair in P-T38-
CPI-17 is stabilized by hydrophobic residues as shown in
Figure 3. In concert withmotion of the A helix, the B/C helix
pair becomes close to the A/D helix pair. This aligns the
four helices into an antiparallel bundle (Table S3). The
average distance between the four helices becomes
15% shorter (Table S3), and the compaction of the struc-
ture causes the overall surface area of the protein to be re-
duced from 7,221 to 6,374 A˚2. Substitution of T38 to Asp1594 Structure 15, 1591–1602, December 2007 ª2007 Elsevierresults in the P loop becoming exposed to solvent, consis-
tent with changes in P form. However, the realignment of
four helices is not evident in the D38 protein relative to
the U-CPI-17, and the overall structure remains V shape
(Figure 3, center).
Formation of Hydrophobic Core
The phosphorylation-induced compression of the four
helices gathers Tyr41 in the P loop, Leu46/Val52 in A helix,
and Ile77/Leu80/Leu81 in B helix into a stable hydropho-
bic core (Figure 4A). For example, the distance between
Val 52 and Ile77 Ca atoms shortens from 19.0 to 6.4 A˚.
Such hydrophobic clustering likely causes changes in
chemical shift of residues around A and B helices (Fig-
ure 1C) and functions to stabilize the antiparallel-aligned
four-helix bundle of P-CPI-17. This stabilization reflects
in higher heteronuclear NOE value of P-T38-CPI-17, com-
pared with U- and D38-CPI-17 (Figure S3). We assayed
thermal stabilities of U- and P-T38-CPI-17, and indeed,
phosphorylation increased the mean melting temperature
Tm from 59
C (U-CPI-17) to 64C (P-T38-CPI-17), showing
an effect on the thermodynamic stability of the protein.We
attribute this change to the hydrophobic core in P-T38-
CPI-17 (Figure 4B). The hydrophobic core is not well
defined in the D38-CPI-17 structure (Figure 4A, middle).
Consistent with this observation, we found the thermal
stability of D38-CPI-17 was lower (Tm = 54
C), compared
to P-T38-CPI-17 (Figure 4B). Overall, the structure and
thermal stability are consistent with the idea thatLtd All rights reserved
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NMR Structure of Phospho-CPI-17Figure 3. Conformational Transition of CPI-17 upon Phosphorylation
U-CPI-17 (1J2M) (left), D38-CPI-17 (1J2N) (middle), and P-T38-CPI-17 (right) are displayed as ribbon structures. Side chains of hydrophobic residues
that tether helix A to D are shown as ball and stick for emphasis.phosphorylation but not mutation to an acidic residue trig-
gers condensation of the protein into a rigid structure, with
a surface topography distinctly different from the unphos-
phorylated protein.
The Hydrophobic Core of P-T38-CPI-17
We examined effects of mutation of residues in the hydro-
phobic core on the inhibition of purified myosin phospha-
tase with wild-type CPI-17 and Y41A, W55A, D73A/E74A,
and I77A/L80A/L81A mutants. All these recombinant
CPI-17 were equally phosphorylated by purified PKC,
suggesting that the mutations do not impair reaction
with Thr38 (Table S4). However, the phosphorylated
mutant CPI-17 showed different inhibitory potency (Fig-
ure 5A). Mutation at either Trp55 or Asp73/Glu74 caused
moderate reduction in inhibitory potency, and the triple
mutation of Ile77/Leu80/Leu81 showed greatly reduced
potency, to an IC50 of around 100 nM. Our previous data
showed that an Ala mutation at Tyr41 (Y41A) eliminated
the inhibitory activity of CPI-17 (Hayashi et al., 2001). Ther-
mal stability of the Y41A protein (Tm = 56
C) was lower
than that of wild-type (Figure 4B, cross). We concluded
that the hydrophobic clustering of Y41 and Ile77/Leu80/
Leu81 was required for potency of CPI-17 as an inhibitor
for myosin phosphatase. The function of CPI-17 mutated
in the hydrophobic core was examined with beta-escin-
permeabilized vas deferens smooth-muscle tissues (Fig-
ure 5B). Because CPI-17 is present at only negligible
levels in vas deferens smooth muscle, phorbol ester
(PDBu, a PKC activator) stimulation does not induce force
production at limiting Ca2+ concentrations (Figure 5B,Structure 15, 1591–160arrowhead) (Woodsome et al., 2001). Doping of recombi-
nant U-CPI-17 into a permeabilized vas deferens smooth-
muscle strip restored PDBu-induced force production
at clamped Ca2+ concentration, suggesting that PKC in-
duced the phosphorylation of CPI-17 causing inhibition
of the endogenous myosin phosphatase in the strip
(Figure 5B, double arrowhead). The triple mutant CPI-17,
I77A/L80A/L81A or Y41A (Figure 5B), did not induce
PKC-mediated smooth-muscle contraction, suggesting
that the formation of hydrophobic core is necessary for
CPI-17 to inhibit myosin phosphatase in tissues. On the
other hand, CPI-17 mutants D73A/E74A and W55A sup-
ported PDBu-induced force production. The maximum
extent and the rate of force development were slightly
lower with these mutant proteins, compared with wild-
type. We note that D73, E74, and W55 are conserved
among CPI-17 proteins from various species, so changes
in these residues have not survived probably because of
the changes in properties.
Modeling of the Interaction between
P-T38-CPI-17 and Myosin Phosphatase
The phospho-pivot computer modeling method was used
to examine hypothetical docking of P-T38-CPI-17 with
myosin phosphatase (Eto et al., 2004; Matsuzawa et al.,
2005a, 2005b). The phosphate group of P-T38-CPI-17
was set into the active site of PP1dMYPT1(1–299) com-
plex (Terrak et al., 2004), and 186,624 in silico complexes
were generated by rotating P-T38-CPI-17 around the
phosphorus atom as a pivot. Each model complex was
scored based on only atomic distances between two2, December 2007 ª2007 Elsevier Ltd All rights reserved 1595
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NMR Structure of Phospho-CPI-17Figure 4. Formation of the Hydrophobic Core in P-CPI-17
(A) Top, middle, and bottom panels represent the structures of U-,
D38-, and P-T38-CPI-17, respectively. Hydrophobic side chains
responsible for the condensed conformation are displayed as Corey,
Pauling, and Koltun colored model.
(B) Thermal stability of CPI-17 proteinsmonitored by circular dichroism
(CD). Vertical axis shows relative change of the molar ellipticity at
222 nm at indicated temperature. CD spectrum was measured with
20 mM protein; P-T38-CPI-17 (open circle), U-CPI-17 (closed circle),
D38-CPI-17 (rectangle), and P-T38-CPI-17 (Y41A) (cross), in 50 mM
potassium phosphate buffer (pH 7.0). Mean values from triplicate
assays are shown. Error bars indicate SEM values from three indepen-
dent assays.1596 Structure 15, 1591–1602, December 2007 ª2007 Elsevierproteins. The modeling yields one converged structure of
P-CPI-17 onmyosin phosphatase (Figure 6A). In this com-
plex, the P loop fits in the active site groove of PP1, from
the cavity of ankyrin-repeat domain toward the N-terminal
a-helical segment of MYPT1 (Terrak et al., 2004). This
model suggests that four Arg side chains in P loop,
Arg33, Arg36, Arg43, and Arg44, are involved in the inter-
action with myosin phosphatase, in addition to phospho-
Thr38. This is consistent to our previous results that an Ala
mutation of CPI-17 at Arg43 and Arg44 impairs the inhib-
itory potency over 40-fold (Hayashi et al., 2001). Interest-
ingly, this model positions N-terminal a-helical segment
of MYPT1 in close proximity to P-T38-CPI-17 (Figure 6A).
Binding of P-T38-CPI-17 to MYPT1
Experimental testing of this model with immobilized
peptides corresponding to MYPT1 segments (1–19) and
(24–41) showed binding of P-T38-CPI-17 to MYPT1(1–
19), but not to MYPT1(24–41) (Figure 6B). Furthermore,
we examined the role of MYPT1 N-terminal segment by
pull-down assay with recombinant myosin phosphatase
complex (Figure 6C). Myosin phosphatase complexes,
consisting of myc-tagged MYPT1(1–300) or MYPT1(18–
300) with HA-tagged PP1 delta were generated in
HEK293 cells by transient transfection, as described pre-
viously (Eto et al., 2005). The cotransfection method pro-
duces active form ofmyosin phosphatase complex in cells
(Eto et al., 2005). Approximately equivalent amounts of
myc-MYPT1 were detected in the lysates by immunoblot-
ting with anti-myc antibody (Figure 6C, left). However, the
binding of myc-MYPT1(18–300) to thioP-CPI-17 beads
was ten times weaker, compared with (1–300) (Figure 6C,
left). Taken together, these data show the N-terminal
a-helical segment of MYPT1 in myosin phosphatase
complex contributes to the interaction with P-CPI-17.
DISCUSSION
From comparison of the structures of the inactive U-CPI-
17 and the active P-T38-CPI-17, we identify a conforma-
tional transition upon phosphorylation of CPI-17 at
Thr38. The phosphorylation induces a swing of the P
loop and a formation of the hydrophobic core to lock and
stabilize a condensed active conformation of P-T38-CPI-
17. Compared with residues in P loop and Leu46, changes
in chemical shift of I77/L80/81 were relatively small. Pre-
sumably, interactions with side chains of Y41 and L46
give a minimum effect on the hydrophobic environment
in the cluster of I77/L80/81, which is evident in the unphos-
pho form. Nonetheless, an environmental change around
B helix is detected as a cluster of chemical shift changes.
Besides, Ala-substitution mutants clearly demonstrate
a major contribution of hydrophobic side chains of I77/
L80/81 to the inhibitory potency. Therefore, we conclude
that this swing-and-lock mechanism of CPI-17 is respon-
sible for potent and specific inhibition of myosin phospha-
tase to switch phosphorylation levels of myosin andmerlin
in response to G-protein activation. All PP1-specific inhib-
itor proteins are regulated by phosphorylation, and five ofLtd All rights reserved
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NMR Structure of Phospho-CPI-17Figure 5. Effects of the Mutation in the Hydrophobic Core on the Inhibitory Potency of CPI-17
(A) Inhibition of myosin phosphatase purified from pig aorta. The myosin phosphatase activity without inhibitor proteins was set as 100%. Data are
averaged from two independent assays done in duplicate.
(B) Forcemeasurement of vas deferens smooth-muscle strip. Panels represent the time-dependent force trace with U-CPI-17: wild-type, D73A/E74A,
I77A/L80A/L81A, andW55A. The rabbit vas deferens smooth-muscle strips were permeabilizedwith beta-escin. TheCPI-17 proteins were doped into
the tissue after the addition of PDBu. The extent of contraction in the presence of 1 mM Ca2+ is set as 100% value.them are in the CPI-17 family, based on the similarity of the
sequences including residues in the hydrophobic core
identified here by NMR, so these results should apply to
other CPI-17 family members. On the other hand, phos-Structure 15, 1591–160phorylation of another class of PP1 inhibitors, inhibitor-1
and DARPP-32, apparently only induces a minor confor-
mational change in the molecule, despite over 1,000-fold
increase in the inhibitory potency (Endo et al., 1996;2, December 2007 ª2007 Elsevier Ltd All rights reserved 1597
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NMR Structure of Phospho-CPI-17Figure 6. Interaction of P-CPI-17 with PP1MYPT1 Complex
(A) Hypothetical 3D model of MYPT1(1–299)PP1P-CPI-17 complex.
The coordinates of MYPT1(1–299)PP1 complex (PDB code: 1S70)
were used for computer modeling of the complex. MYPT1 (yellow)
and PP1 (cyan) are depicted in a surface model, and P-T38-CPI-17
is drawn as a ribbon structure. The positive charge of MYPT1 Asp5
is shown as red, and the side chains of phospho-Thr38 and Arg43/
44 in CPI-17 are shown as ball-and-stick.
(B) Direct binding of P-CPI-17 with MYPT1(1–19) peptide. Binding
assay of P-T38-CPI-17 was performed with synthetic peptides corre-
sponding to MYPT1 segments (1–19) and (24–41), immobilized on1598 Structure 15, 1591–1602, December 2007 ª2007 ElsevierNeyroz et al., 1993). The phosphorylation-induced confor-
mational switch seems to be a unique feature in theCPI-17
family of PPI inhibitor proteins.
Asp- or Glu-substitution of Ser or Thr is often used for
mimicking phosphorylation of proteins. One example is
the activation loop of protein kinases. Phosphorylation of
protein kinases in the activation loop is required for full
activity, and it can be mimicked by substitution with Asp
or Glu (Zhang et al., 1995). The phosphate group in the ac-
tivation loop of kinases directly forms salt bridges with Arg
residues in N-terminal domain (Canagarajah et al., 1997;
Johnson et al., 1996), and the effectiveness of Glu or Asp
suggests these residues can form salt bridges with the
same Arg. In contrast, the phosphate of P-T38-CPI-17 is
exposed to solvent and interacts instead with the active
site of PP1 in myosin phosphatase. Asp substitution at
Thr38 induces a swing of the P loop but not the same re-
alignment of helices or formation of the hydrophobic core
in the protein as is formed when T38 is phosphorylated
(Ohki et al., 2003). The failure of hydrophobic clustering in
D38-CPI-17 is evidenced by lower thermal stability. With-
out thehydrophobiccore there is a 100-fold lower inhibitory
potency of D38-CPI-17 compared to P-T38-CPI-17. Thus,
the negative charge of a carboxyl group is insufficient for
completion of the conformational switching in CPI-17.
This gives an example of where an acidic side chain is
not phosphomimetic, offering a note of caution to the com-
mon practice of using properties of mutated proteins to
make conclusions about effects of phosphorylation.
Currently, about 150 protein structures with phospho-
Thr are listed in the Protein Data Bank (PDB). In most
cases, the phosphate group is directly tethered to other
residues in the same protein via salt bridges and/or hydro-
gen bonds. In this way, the phosphate drives formation of
a new protein conformation that is stabilized by these in-
tramolecular interactions, as seen in glycogen phosphor-
ylase-a and protein kinases (Johnson et al., 1996; Sprang
et al., 1988). Another example is the NMR structure of a 44
residue P-Thr peptide mimicking the forkhead-associated
(FHA) domain of human Ki67 protein in the complex with
its receptor, the human nucleolar protein hNIHK, where
the phosphate functions as a ligand (Byeon et al., 2005).
Our studies reveal a different mechanism of phosphor-
ylation-induced conformational change. The phospho
agarose beads. Bound P-T38-CPI-17 was quantified by immunoblot-
ting with anti-CPI-17 antibody (top). Normalized values are repre-
sented as a bar graph. Student’s t test was used to assess signifi-
cance, and asterisk and double asterisk indicate p > 0.15 and p <
0.03, respectively. Error bars indicate SEM values from three indepen-
dent assays.
(C) Pull-down assay of myc-MYPT1PP1 complex and P-CPI-17. Re-
combinant myc-MYPT1(1–300) and myc- MYPT1(18–300) were tran-
siently expressed in HEK293 cells, and the crude lysates were used
as a source of recombinant myosin phosphatase complex. Panels
demonstrate immunoblots with anti-myc antibody for myc-MYPT1 in
cell lysates (left) and in the fraction bound to thiophospho-CPI-17
beads (right). Bound myc-MYPT1 was normalized against that in cell
lysate, and mean values from two independent experiments are repre-
sented under each lane.Ltd All rights reserved
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NMR Structure of Phospho-CPI-17conformation of the CPI-17 P loop is stabilized without
a hydrogen bond or salt bridge to the phosphate group
from other residues in the protein. Based on heteronuclear
NOEdata, the P loop of unphosphorylatedCPI-17 is highly
flexible, and this presumably exposes Thr38 to kinases,
such as PKC and ROCK. Upon the phosphorylation of
T38, the side chains of neighboring V37, V39, and Y41 an-
chor the P loop to the hydrophobic core formed between
the helices that restrains the overall solution structure. The
rigid structure of phosphorylated P loop is likely critical for
the potent inhibition of the phosphatase by positioning the
phosphate relative to other residues in CPI-17 that form
contacts with MYPT1 and PP1. When the hydrophobic
core of P-T38-CPI-17 is perturbed by Ala substitution of
Tyr41, the P-Thr38 residue is readily dephosphorylated
by myosin phosphatase (Hayashi et al., 2001). We pro-
pose that the rigidity of the structure due to the hydropho-
bic core is key to preventing hydrolysis of the P-T38,
making P-T38-CPI-17 an inhibitor instead of a substrate.
Thus, the swing-and-lock mechanism of CPI-17 activation
restricts flexibility of the P loop and protects P-Thr38 from
being hydrolyzed at the active site of myosin phospha-
tase. Interestingly, P-T38 is hydrolyzed by other PP1 holo-
enzymes, such as glycogen phosphatase (a heterodimer
of PP1 plus GM subunit; Eto et al., 2004), so phospho-
CPI-17 is both a substrate and an inhibitor, depending
on the form of PP1 it encounters.
Previously, phospho-pivot modeling with D38-CPI-17
(PDB code: 1J2N) and monomeric PP1 alpha isoform
catalytic subunit (PDB code: 1IT6) predicted critical roles
for residues at the active site of PP1d, namely D137,
D193, R220, Y271, and E274. Indeed, these residues are
necessary for the binding of PP1 d with P-T38-CPI-17 in
an in vitro assay (Matsuzawa et al., 2005a). These same
residues at the PP1 active site seem to be involved
in the model of the P-T38-CPI-17PP1dMYPT1(1–299)
complex. However, the best fitting model was obtained
when the pivot phosphorus atom was set at a position
0.5 A˚ away from the active site. Thus, the phosphate group
is not in an optimum position for hydrolysis in this model.
We speculate that weak interactions of theMYPT1 subunit
with P-T38-CPI-17, perhaps involving Asp5 of MYPT1
N-terminal segment and Arg44 of P-CPI-17 (Figure 6A),
displaces phospho-Thr38 from being in an optimum posi-
tion at the PP1 active site for dephosphorylation. Some in-
volvement of MYPT1 seems to be needed to account for
the inhibitor versus substrate reaction of P-T38-CPI-17
with different PP1 holoenzymes.
It is noteworthy that the phospho-pivot model positions
the unstructured N-terminal tail of CPI-17 near the MYPT1
ankyrin repeat domain. Other CPI-17 family members,
PHI-1 and KEPI, also inhibit myosin phosphatase, but
with different potencies. The IC50 for PHI-1 (50 nM) is
50-fold higher than that for CPI-17, whereas KEPI inhibits
myosin phosphatase with IC50 of 0.1 nM (Erdodi et al.,
2003; Eto et al., 1999). It is possible that the N-terminal
tail of the different CPI-17 family members functions as
a sensor for different regulatory subunits of PP1. This
gives us a future direction for studying functional diversityStructure 15, 1591–160in the CPI-17 family. Despite a focus on the MYPT1 N-ter-
minal domain, we cannot completely rule out involvement
of the MYPT1 C-terminal domain and/or the M21 subunit
in specific recognition of P-CPI-17. Other PP1 inhibitor
proteins are known to contact both PP1 catalytic and reg-
ulatory subunits to form trimeric complexes that account
for their selective inhibition of PP1 in different contexts.
One example is inhibitor-1 binding to GADD-34 that is
bound to PP1, and other examples are inhibitor-2 binding
to either neurabin or KPI-2 that both bind PP1 at indepen-
dent sites. (Connor et al., 2001; Terry-Lorenzo et al., 2002;
Wang and Brautigan, 2002). PP1 inhibitor proteins also
bind to PP1 holoenzymes without direct contact to regula-
tory subunits, such as heterotrimers of inhibitor-2 with
Nek2APP1 (Eto et al., 2002b; Li et al., 2007) and inhibi-
tor-3 with sds22PP1 (Lesage et al., 2007). Direct contact
between regulatory subunits and PP1 inhibitor proteins is
an attractive idea to provide signaling specificity for con-
trolling individual PP1 complexes. The structure of an
activated PP1 inhibitor gives general insight into phos-
phorylation-dependent conformational changes and reg-
ulation of cellular PP1, and opens a door to understanding
mechanisms of signaling crosstalk between kinases and
phosphatases.
EXPERIMENTAL PROCEDURES
Proteins
The cDNA of CPI-17 was cloned from pig aorta smooth muscle library.
Recombinant CPI-17(22–120) for NMR was prepared with pET30 bac-
terial expression vector with theminimalmedium containing 15N-amm-
noniumchloride and/or 13C-glucose as the sole source of nitrogen and/
or carbon. This method yields the uniformly stable-isotope-labeled
(>95%) sample for NMR spectroscopy (Ohki et al., 2001, 2003). CPI-
17 proteins for other assays are expressed as full-length versions
with N-terminal His6- and S-tag sequences (Eto et al., 2003). Phos-
phorylation of the protein was performed with an active fragment of
PKC. The active fragment of PKC was extracted from human red cells
with hypotonic buffer and purified by ammonium-sulfate precipitation
and sequential column chromatography with DEAE-Sepharose, Phe-
nyl-Sepharose, Q-Sepharose, and Protamine-agarose. Stoichiometric
phosphorylation of CPI-17 was verified by urea-PAGE analysis (Fig-
ure S1), as described previously (Eto et al., 2003). Anti-P-T38-CPI-17
IgY was prepared by using synthetic phospho-peptide as an antigen
(Aves Lab, Tigard, OR) and purified by affinity chromatography, as
described previously (Kitazawa et al., 2000).
NMR Structure Determination
All NMR data for 1 mM P-T38-CPI-17 (in 50 mM phosphate buffer
[pH 6.8], 100 mM KCl, 1 mM DTT, and 0.02% NaN3) were recorded
on a Varian INOVA750 spectrometer. The sample temperature was
kept at 25.0C. A set of two- and three-dimensional NMR data was ob-
tained for resonance assignments (Bax and Pochapsky, 1992). Homo-
nuclear 2D-NOESY, 15N-edited NOESY, and 13C-edited NOESY with
mixing time of 100 ms were recorded to collect distance information.
To obtain the information about hydrogen bonding, amide proton
H-D exchange was monitored by 1H-15N HSQC. 2D-HMQC-J spectra
were also recorded to obtain dihedral angle constraints. All NMR data
were processedwith nmrPipe/nmrDraw (Delaglio et al., 1995) andwere
analyzed with PIPP (Garrett et al., 1991). Structure calculation was
carried out with X-PLOR version 3.851 (Brunger et al., 1998; Kleywegt
and Jones, 1998). Quality of each coordinate was examined by using
AQUA/procheck-NMR (Laskowski et al., 1996). The Ramachandran
plot analysis of the final structures showed that 1.7 ± 1.1% of2, December 2007 ª2007 Elsevier Ltd All rights reserved 1599
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The extent of chemical-shift changes of U- and P-CPI-17 proteins
(Dd) was calculated from the chemical shift value of proton (dH) and
nitrogen (dN) in HSQC data by use of equation Dd (chemical shift
change) = ([dH(U) – dH(P)]
2 + 0.25[dN(U)  dN(P)]2)1/2.
Structural Analysis
All structural images were drawn with MOLMOL (Koradi et al., 1996),
Molscript (Kraulis, 1991), and Raster3D (Merrit and Bacon, 1997). Vec-
tor geometry mapping and calculations of surface potential and area
were done by using an algorithm of Yap et al. (Yap et al., 2002) and
PyMol Molecular Graphic System (http://www.pymol.org/), respec-
tively. The rotation angle of A helix was estimated from mean value
of differences on Calpha-Cbeta angle of each residue.
Phospho-Pivot Modeling
An in silico model of the ternary complex, P-T38-CPI-17/PP1 delta/
MYPT1(1–299), was obtained by the phospho-pivot modelingmethod,
as described previously (Matsuzawa et al., 2005a, 2005b). Structural
data of P-T38-CPI-17 (present study) and the myosin phosphatase
complex of MYPT1(1–299) and PP1 delta (Terrak et al., 2004) were
used for the modeling. The best result was obtained when the phos-
phate group of P-CPI-17 was placed at a point 0.5 A˚ away from the pu-
tative phosphorus position. The atomic distance violation was set with
the threshold of 3.5 A˚ (Ca-Ca) or 2.0 A˚ (N-O, N-N, O-O). Models without
distance violation between main chain atoms, identified as 68 out of
186,624 models, were subjected to an energy minimization process
with permitted of structural adjustments on both molecules, by using
AMBER force field on SYBYL/BIOPOLYMER (Tripos, Inc.). In this mod-
eling, atoms within 8 A˚ of CPI-17 were used for the energy calculation.
The results of energy minimization are shown in Table S5. The orienta-
tion of P-CPI-17 against MYPT1PP1 complex is the same in four of
the best five models. Both electrostatic and hydrogen-bonding energy
values dominantly contribute to the total binding force. The best model
(shown in Figure 6A) includes 15 atomic violations.
Assays
CD spectrum measurements were performed on a JASCO 720 spec-
tropolarimeter at various temperatures (20C–95C) with 20 mM U-
and H6S-P-T38-CPI-17 full-length proteins in phosphate-buffered
saline. Thermal stability of CPI-17 was assessed via the melting tem-
perature (Tm) from the plot of molar ellipticity at 222 nm against the
temperature. Other assays were carried out at 20C. The H6S-tag
does not affect the CD spectrum (data not shown). The inhibitory po-
tency of CPI-17 proteins was measured by using myosin phosphatase
purified from pig aorta smooth muscle with 0.5 mM 32P-labeled phos-
pho-myosin light chain as a substrate, at 20C (Eto et al., 2003). The
Ca2+ sensitizing effect of CPI-17 protein was examined at 20C in
vas deferens smooth-muscle strips permeabilized with beta-escin
(Masuo et al., 1994). This tissue preparation includes a minimum
amount of endogenous CPI-17 but retains other regulatory proteins,
such as myosin phosphatase, PKC, and ROCK (Woodsome et al.,
2001). Binding assay of P-CPI-17 was performed with synthetic seg-
ments of MYPT1(1–19) and MYPT1(24–41) (GenScript, Piscataway,
NJ). MYPT1(1–19) and MYPT1(24–41) peptides were immobilized
onto Sulfo-link beads (Pierce) via a C-terminal Cys residue added for
crosslinking, and then excess reactive groups on the beads were
quenched with 50 mM L-Cys. Blank beads for controls were treated
with 50 mM L-Cys without peptide conjugation. H6S-P-T38-CPI-17
(0.1 mM) was mixed for 30 min at 23C, with 10 ml of slurry in 150 ml
of buffer A (50 mM MOPS-NaOH [pH 7.0] including 0.1 M NaCl,
1 mM EGTA, 0.1% Tween 20, 5% glycerol, 0.4 mM Pefabloc, and
0.5 mM TCEP). The beads were washed three times with 100 ml of
buffer A, and bound CPI-17 was detected by immunoblotting with
anti-CPI-17 by using FluoroChemSP CCD imaging system (Alpha-
Innotech). Relative amount of bound CPI-17 was obtained from three
independent experiments by quantifying the band intensity with Al-
phaEace FC imaging software. Pull-down assay of myc-MYPT1PP11600 Structure 15, 1591–1602, December 2007 ª2007 Elseviercomplex was performed by the method described previously (Eto
et al., 2004). Briefly, HEK293 cells (60mmdish) in Dulbecco’s modified
eaglemedium supplemented with 10% fetal bovine serum (Mediatech,
VA) were transiently transfected for 24 hr with 3.5 mg of myc-MYPT1(1–
300) or myc- MYPT1(18–300) vector plus 0.5 mg of HA-PP1 delta vec-
tor with FuGENE6 transfection reagent (Roche). Empty vector without
insert DNA were used as negative control. Cells were scraped off with
0.5 ml of buffer A and incubated for 10 min on ice. The homogenate
was clarified by centrifugation for 10 min at 20,000 3 g. The lysates
were subjected to pull-down assay with thiophospho-CPI-17 beads.
Thiophospho-CPI-17 was coupled with S-protein beads though
S-tag sequence in the recombinant protein (Eto et al., 2004). After
washing the beads, proteins bound to the beads were eluted with
30 ml of Laemmli buffer, and the samples were subjected to immuno-
blotting with anti-myc antibody (9E10). Staining intensity of myc-
MYPT1 peptide was quantified by densitometry, described above.
Supplemental Data
Supplemental Data include phosphorylation of CPI-17(22–120)
(Figure S1), zoomed HQSC spectrum (Figure S2), NOESY spectrum
(Figure S3), heteronuclear NOE (Figure S4), statistics for NMR struc-
ture (Table S1), comparison of helix region between unphospho and
phospho forms (Table S2), interhelical angles and distances (Table
S3), phosphorylation of CPI-17mutants (Table S4), and binding energy
of P-CPI-17 and MYPT1PP1 complex (Table S5) and are available at
http://www.structure.org/cgi/content/full/15/12/1591/DC1/.
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